Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HYPERLIPIDEMIA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HYPERLIPIDEMIA MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HYPERLIPIDEMIA MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET HYPERLEPIDEMIA MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR HYPERLEPIDEMIA S MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR HYPERLEPIDEMIA MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE HYPERLEPIDEMIA MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR HYPERLEPIDEMIA MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 OPPUTUNITY MAP ANALYSIS
16 VALUE CHAIN ANALYSIS
17 HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
17.1 ECONOMIC DEVELOPMENT
18 GLOBAL HYPERLEPIDEMIA MARKET, BY TYPE
18.1 OVERVIEW
18.2 FAMILIAL
18.3 ACQUIRED
19 GLOBAL HYPERLEPIDEMIA MARKET, BY TREATMENT
19.1 OVERVIEW
19.2 STATINS
19.2.1 BY TYPE
19.2.1.1. ATORVASTATIN
19.2.1.2. SIMVASTATIN
19.2.1.3. ROSUVASTATIN
19.2.1.4. PRAVASTATIN
19.2.1.5. LOVASTATIN
19.2.1.6. FLUVASTATIN
19.2.1.7. PITAVASTATIN
19.2.1.8. OTHERS
19.2.2 BY DRUG CLASS
19.2.2.1. BRANDED
19.2.2.1.1. LIPITOR
19.2.2.1.2. ZOCOR
19.2.2.1.3. OTHERS
19.2.2.2. GENERIC
19.3 BILE ACID SEQUESTRANTS
19.3.1 BY TYPE
19.3.1.1. HOLESTYRAMINE
19.3.1.2. COLESEVELAM
19.3.1.3. COLESTIPOL
19.3.1.4. OTHERS
19.3.2 BY DRUG CLASS
19.3.2.1. BRANDED
19.3.2.1.1. QUESTRAN
19.3.2.1.2. WELCHOL
19.3.2.1.3. OTHERS
19.3.2.2. GENERIC
19.4 FIBRIC ACID DERIVATIVES
19.4.1 BY TYPE
19.4.1.1. FENOFIBRATE
19.4.1.2. GEMFIBROZIL
19.4.1.3. OTHERS
19.4.2 BY DRUG CLASS
19.4.2.1. BRANDED
19.4.2.1.1. LOPID
19.4.2.1.2. TRILIPIX
19.4.2.1.3. OTHERS
19.4.2.2. GENERIC
19.5 PCSK9 INHIBITORS
19.5.1 BY TYPE
19.5.1.1. ALIROCUMAB
19.5.1.2. EVOLOCUMAB
19.5.1.3. OTHERS
19.5.2 BY DRUG CLASS
19.5.2.1. BRANDED
19.5.2.1.1. PRALUENT
19.5.2.1.2. OTHERS
19.5.2.2. GENERIC
19.6 COMBINATION
19.6.1 BY TYPE
19.6.1.1. EZETIMIBE/SIMVASTATIN
19.6.1.2. EZETIMIBE/ATORVASTATIN
19.6.1.3. EZETIMIBE/ROSUVASTATIN
19.6.1.4. AMLODIPINE/ATORVASTATIN
19.6.1.5. OTHERS
19.6.2 BY DRUG CLASS
19.6.2.1. BRANDED
19.6.2.2. GENERIC
19.7 CHOLESTEROL ABSORPTION INHIBITORS
19.7.1 BY DRUG CLASS
19.7.1.1. BRANDED
19.7.1.2. GENERIC
19.8 MISCELLANEOUS ANTIHYPERLIPIDEMIC AGENTS
19.8.1 BY DRUG CLASS
19.8.1.1. BRANDED
19.8.1.2. GENERIC
19.9 OTHERS
20 GLOBAL HYPERLEPIDEMIA MARKET, BY DRUGS CLASS
20.1 OVERVIEW
20.2 BRANDED
20.3 GENERICS
21 GLOBAL HYPERLEPIDEMIA MARKET, BY TYPE
21.1 OVERVIEW
21.2 MARKETED
21.3 PIPELINE
22 GLOBAL HYPERLEPIDEMIA MARKET, BY AGE GROUP
22.1 OVERVIEW
22.2 PEDIATRIC
22.3 ADULT
22.4 GERIATRIC
23 GLOBAL HYPERLEPIDEMIA MARKET, BY GENDER
23.1 OVERVIEW
23.2 MALE
23.3 FEMALE
24 GLOBAL HYPERLEPIDEMIA MARKET, BY PRESCRIPTION MODE
24.1 OVERVIEW
24.2 OVER THE COUNTER
24.3 PRESCRIPTION BASED
25 GLOBAL HYPERLEPIDEMIA MARKET, BY ROUTE OF ADMINISTRATION
25.1 OVERVIEW
25.2 ORAL
25.3 PARENTERAL
25.4 OTHERS
26 GLOBAL HYPERLEPIDIMIA MARKET, BY END USER
26.1 OVERVIEW
26.2 HOSPITALS
26.2.1 PUBLIC
26.2.2 PRIVATE
26.3 HOMECARE
26.4 AMBULATORY SURGICAL CENTERS
26.5 SPECIALITY CLINICS
26.6 OTHERS.
27 GLOBAL HYPERLEPIDIMIA MARKET, BY DISTRIBUTION CHANNEL
27.1 OVERVIEW
27.2 DIRECT TENDER
27.3 RETAILS SALES
27.3.1 HOPSITAL PHARMACY
27.3.2 RETAIL PHARMACY
27.3.3 ONLINE PHARMACY
27.4 OTHERS
28 GLOBAL HYPERLEPIDIMIA MARKET, BY GEOGRAPHY
28.1 GLOBAL HYPERLEPIDIMIA MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
28.1.1 NORTH AMERICA
28.1.1.1. U.S.
28.1.1.2. CANADA
28.1.1.3. MEXICO
28.1.2 EUROPE
28.1.2.1. GERMANY
28.1.2.2. FRANCE
28.1.2.3. U.K.
28.1.2.4. HUNGARY
28.1.2.5. LITHUANIA
28.1.2.6. AUSTRIA
28.1.2.7. IRELAND
28.1.2.8. NORWAY
28.1.2.9. POLAND
28.1.2.10. ITALY
28.1.2.11. SPAIN
28.1.2.12. RUSSIA
28.1.2.13. TURKEY
28.1.2.14. BELGIUM
28.1.2.15. NETHERLANDS
28.1.2.16. SWITZERLAND
28.1.2.17. REST OF EUROPE
28.1.3 ASIA-PACIFIC
28.1.3.1. JAPAN
28.1.3.2. CHINA
28.1.3.3. SOUTH KOREA
28.1.3.4. INDIA
28.1.3.5. AUSTRALIA
28.1.3.6. SINGAPORE
28.1.3.7. THAILAND
28.1.3.8. MALAYSIA
28.1.3.9. INDONESIA
28.1.3.10. PHILIPPINES
28.1.3.11. VIETNAM
28.1.3.12. REST OF ASIA-PACIFIC
28.1.4 SOUTH AMERICA
28.1.4.1. BRAZIL
28.1.4.2. ARGENTINA
28.1.4.3. PERU
28.1.4.4. REST OF SOUTH AMERICA
28.1.5 MIDDLE EAST AND AFRICA
28.1.5.1. SOUTH AFRICA
28.1.5.2. SAUDI ARABIA
28.1.5.3. UAE
28.1.5.4. EGYPT
28.1.5.5. KUWAIT
28.1.5.6. ISRAEL
28.1.5.7. REST OF MIDDLE EAST AND AFRICA
29 GLOBAL HYPERLEPIDIMIA MARKET, COMPANY LANDSCAPE
29.1 COMPANY SHARE ANALYSIS: GLOBAL
29.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
29.3 COMPANY SHARE ANALYSIS: EUROPE
29.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
29.5 MERGERS & ACQUISITIONS
29.6 NEW PRODUCT DEVELOPMENT & APPROVALS
29.7 EXPANSIONS
29.8 REGULATORY CHANGES
29.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
30 GLOBAL HYPERLEPIDIMIA MARKET, SWOT AND DBMR ANALYSIS
31 GLOBAL HYPERLEPIDIMIA MARKET, COMPANY PROFILE
31.1 PFIZER INC.
31.1.1 COMPANY OVERVIEW
31.1.2 REVENUE ANALYSIS
31.1.3 GEOGRAPHIC PRESENCE
31.1.4 PRODUCT PORTFOLIO
31.1.5 RECENT DEVELOPMENTS
31.2 F. HOFFMANN-LA ROCHE AG
31.2.1 COMPANY OVERVIEW
31.2.2 REVENUE ANALYSIS
31.2.3 GEOGRAPHIC PRESENCE
31.2.4 PRODUCT PORTFOLIO
31.2.5 RECENT DEVELOPMENTS
31.3 SANOFI
31.3.1 COMPANY OVERVIEW
31.3.2 REVENUE ANALYSIS
31.3.3 GEOGRAPHIC PRESENCE
31.3.4 PRODUCT PORTFOLIO
31.3.5 RECENT DEVELOPMENTS
31.4 MYLAN N.V.
31.4.1 COMPANY OVERVIEW
31.4.2 REVENUE ANALYSIS
31.4.3 GEOGRAPHIC PRESENCE
31.4.4 PRODUCT PORTFOLIO
31.4.5 RECENT DEVELOPMENTS
31.5 GLAXOSMITHKLINE PLC
31.5.1 COMPANY OVERVIEW
31.5.2 REVENUE ANALYSIS
31.5.3 GEOGRAPHIC PRESENCE
31.5.4 PRODUCT PORTFOLIO
31.5.5 RECENT DEVELOPMENTS
31.6 B. BRAUN MEDICAL INC
31.6.1 COMPANY OVERVIEW
31.6.2 REVENUE ANALYSIS
31.6.3 GEOGRAPHIC PRESENCE
31.6.4 PRODUCT PORTFOLIO
31.6.5 RECENT DEVELOPMENTS
31.7 TARO PHARMACEUTICAL INDUSTRIES LTD.
31.7.1 COMPANY OVERVIEW
31.7.2 REVENUE ANALYSIS
31.7.3 GEOGRAPHIC PRESENCE
31.7.4 PRODUCT PORTFOLIO
31.7.5 RECENT DEVELOPMENTS
31.8 ASTRA ZENECA
31.8.1 COMPANY OVERVIEW
31.8.2 REVENUE ANALYSIS
31.8.3 GEOGRAPHIC PRESENCE
31.8.4 PRODUCT PORTFOLIO
31.8.5 RECENT DEVELOPMENTS
31.9 NOVARTIS AG
31.9.1 COMPANY OVERVIEW
31.9.2 REVENUE ANALYSIS
31.9.3 GEOGRAPHIC PRESENCE
31.9.4 PRODUCT PORTFOLIO
31.9.5 RECENT DEVELOPMENTS
31.1 MERCK & CO., INC.
31.10.1 COMPANY OVERVIEW
31.10.2 REVENUE ANALYSIS
31.10.3 GEOGRAPHIC PRESENCE
31.10.4 PRODUCT PORTFOLIO
31.10.5 RECENT DEVELOPMENTS
31.11 BRISTOL MYERS SQUIBB
31.11.1 COMPANY OVERVIEW
31.11.2 REVENUE ANALYSIS
31.11.3 GEOGRAPHIC PRESENCE
31.11.4 PRODUCT PORTFOLIO
31.11.5 RECENT DEVELOPMENTS
31.12 ELI LILLY AND COMPANY
31.12.1 COMPANY OVERVIEW
31.12.2 REVENUE ANALYSIS
31.12.3 GEOGRAPHIC PRESENCE
31.12.4 PRODUCT PORTFOLIO
31.12.5 RECENT DEVELOPMENTS
31.13 REGENERON PHARMACEUTICALS INC.
31.13.1 COMPANY OVERVIEW
31.13.2 REVENUE ANALYSIS
31.13.3 GEOGRAPHIC PRESENCE
31.13.4 PRODUCT PORTFOLIO
31.13.5 RECENT DEVELOPMENTS
31.14 AMGEN INC.
31.14.1 COMPANY OVERVIEW
31.14.2 REVENUE ANALYSIS
31.14.3 GEOGRAPHIC PRESENCE
31.14.4 PRODUCT PORTFOLIO
31.14.5 RECENT DEVELOPMENTS
31.15 DAIICHI SANKYO COMPANY, LIMITED.
31.15.1 COMPANY OVERVIEW
31.15.2 REVENUE ANALYSIS
31.15.3 GEOGRAPHIC PRESENCE
31.15.4 PRODUCT PORTFOLIO
31.15.5 RECENT DEVELOPMENTS
31.16 ALNYLAM PHARMACEUTICALS, INC.
31.16.1 COMPANY OVERVIEW
31.16.2 REVENUE ANALYSIS
31.16.3 GEOGRAPHIC PRESENCE
31.16.4 PRODUCT PORTFOLIO
31.16.5 RECENT DEVELOPMENTS
31.17 DR. REDDY'S LABORATORIES LTD.
31.17.1 COMPANY OVERVIEW
31.17.2 REVENUE ANALYSIS
31.17.3 GEOGRAPHIC PRESENCE
31.17.4 PRODUCT PORTFOLIO
31.17.5 RECENT DEVELOPMENTS
31.18 ESPERION THERAPEUTICS, INC.
31.18.1 COMPANY OVERVIEW
31.18.2 REVENUE ANALYSIS
31.18.3 GEOGRAPHIC PRESENCE
31.18.4 PRODUCT PORTFOLIO
31.18.5 RECENT DEVELOPMENTS
31.19 ABBVIE, INC.
31.19.1 COMPANY OVERVIEW
31.19.2 REVENUE ANALYSIS
31.19.3 GEOGRAPHIC PRESENCE
31.19.4 PRODUCT PORTFOLIO
31.19.5 RECENT DEVELOPMENTS
31.2 FORMAC PHARMACEUTICALS N.V.
31.20.1 COMPANY OVERVIEW
31.20.2 REVENUE ANALYSIS
31.20.3 GEOGRAPHIC PRESENCE
31.20.4 PRODUCT PORTFOLIO
31.20.5 RECENT DEVELOPMENTS
31.21 ZYDUS LIFESCIENCES
31.21.1 COMPANY OVERVIEW
31.21.2 REVENUE ANALYSIS
31.21.3 GEOGRAPHIC PRESENCE
31.21.4 PRODUCT PORTFOLIO
31.21.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
32 RELATED REPORTS
33 CONCLUSION
34 QUESTIONNAIRE
35 ABOUT DATA BRIDGE MARKET RESEARCH
